Old GBA favorite: HealthEquity (NASDAQ:HQY – Get Rating) is set to announce its earnings results after the market closes on Tuesday, September 6th. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link. HealthEquity (NASDAQ:HQY – Get Rating) last released its quarterly earnings data on Monday, June 6th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. HealthEquity had a positive return on equity of 3.03% and a negative net margin of 7.11%. The company had revenue of $205.68 million for the quarter, compared to analysts’ expectations of $202.72 million. During the same period last year, the firm posted $0.25 earnings per share. On average, analysts expect HealthEquity to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year. Get HealthEquity alerts: HealthEquity Price Performance HealthEquity stock opened at $63.99 on Monday. HealthEquity has a one year low of $36.81 and a one year high of $73.29. The stock has a market capitalization of $5.40 billion, a PE ratio of -96.95, a price-to-earnings-growth ratio of 4.82 and a beta of 0.96. The business’s fifty day moving average is $60.90 and its 200 day moving average is $61.17. Analyst Upgrades and Downgrades Several equities research analysts recently commented on HQY shares. The Goldman Sachs Group began coverage on HealthEquity in a research report on Tuesday, July 12th. They set a “sell” rating and a $59.00 price objective on the stock. Barrington Research increased their target price on HealthEquity from $70.00 to $75.00 in a report on Tuesday, June 7th. Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $66.00 to $67.00 in a report on Wednesday, June 8th. Finally, SVB Leerink increased their target price on HealthEquity from $67.00 to $76.00 and gave the company an “outperform” rating in a report on Tuesday, June 7th. Two analysts have rated the stock with a sell rating and ten have given a buy rating to the company. According to data from MarketBeat.com, HealthEquity currently has an average rating of “Moderate Buy” and an average target price of $74.33. Insider Transactions at HealthEquity In other news, COO Edward Bloomberg sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $57.63, for a total value of $57,630.00. Following the transaction, the chief operating officer now owns 59,850 shares of the company’s stock, valued at $3,449,155.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.80% of the company’s stock. Institutional Trading of HealthEquity Several institutional investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans grew its position in shares of HealthEquity by 0.5% during the second quarter. Thrivent Financial for Lutherans now owns 59,470 shares of the company’s stock worth $3,651,000 after purchasing an additional 287 shares in the last quarter. Yousif Capital Management LLC grew its holdings in HealthEquity by 0.9% during the 1st quarter. Yousif Capital Management LLC now owns 44,312 shares of the company’s stock valued at $2,988,000 after buying an additional 410 shares in the last quarter. UBS Group AG grew its holdings in HealthEquity by 1.6% during the 1st quarter. UBS Group AG now owns 32,908 shares of the company’s stock valued at $2,220,000 after buying an additional 513 shares in the last quarter. Captrust Financial Advisors grew its holdings in HealthEquity by 92.5% during the 1st quarter. Captrust Financial Advisors now owns 1,176 shares of the company’s stock valued at $79,000 after buying an additional 565 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in HealthEquity by 0.7% during the 2nd quarter. Legal & General Group Plc now owns 126,275 shares of the company’s stock valued at $7,752,000 after buying an additional 844 shares in the last quarter. Hedge funds and other institutional investors own 99.43% of the company’s stock. About HealthEquity (Get Rating) HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. HQY $63.00
Stoney.. when the dust settled, you were down twice that much in one day. The same day you post it! As I type, the futures are green, so one can assume you'll be on here tomorrow morning crowing about your great market vision.... but we're gonna nip this in the bud. In case you haven't noticed, the indices as of late, go up and and down 1% plus daily. To be a savant... one must have a longer term time-frame... and that does not include a post saying the S&P will range between 3800-4200. Come on Stoney... Muttley could have typed that one.... had her fingernails been clipped. I know this kills you, but I'll post a picture. This is what the readers have come to depend on. 83K views... plus the behind the scenes kids at Cramers and those at the CNBC morning lineup... >>> And there were NO UPDATES IN BETWEEN THESE CALLS Readers that have been here awhile remember my posts on the day of 12/16/21. The perfect market top call. Some say, it is as memorable as Erin Burnett interviewing Cramer when he went on a rant in 2007. Perhaps, but I didn't yell. Soooo... Leave the intraday stuff to the intraday players. And leave the bigger picture to VZ. These things require an advanced handle on market psychology.... one born in the fire of the real world... but bred in the unquestionable (and ironically provincial!) mindset of the "smarter than you" Wall Street player crowd. Sheep. Stick with finding GBA biotechs Stoney.... your skill lies there. Not in the bigger picture.
GM/GM Our first letter in a while! Dear GBA you are incredible. Last week I took your advice on the S&P and I made $8,000 dollars! I have never made so much in my life! I then did a earnings play on your Pure Storage and netted $2 after hours! And this is after I daytraded your CELH gummy for $8 AND a second gummy of GNRC for $10. Do you realize in one week what you did! And in a falling market. i have never been so impressed and never made so much dough. Keep it up! All I can say is Phew! Now I am in Sentnial 1 and lets do this! signed George from Ct.
--DraftKings price target raised to $24 from $20 at Susquehanna 07:13 DKNG Susquehanna analyst Joseph Stauff raised the firm's price target on DraftKings to $24 from $20 and keeps a Positive rating on the shares. The analyst noted they achieved incremental cost savings of $40m in 1Q and $60m in 2Q yet still grew users +30% in 1H 2022 and he thinks this is notable considering management's "shift" to profitable growth from investment in TAM expansion last year.
--BofA starts Dropbox at Buy, sees 'strong monetization engine' 06:37 DBX As previously reported, BofA analyst Michael Funk initiated coverage of Dropbox with a Buy rating and $34 price target, citing its strong free cash flow generation and potential for incremental returns to shareholders, upside he sees to consensus estimates and what he calls "a business model and valuation that was largely untouched by the pandemic." Dropbox's large user base and low customer acquisition costs give it a "strong monetization engine," Funk added.
Ironwood announces LINZESS trial met primary, secondary endpoints 07:13 IRWD Ironwood announced topline data from a Phase III clinical trial evaluating LINZESS 72 mcg in pediatric patients aged 6-17 with functional constipation, or FC. The trial met its primary and secondary endpoints, demonstrating that linaclotide improved frequency of spontaneous bowl movements, or SBM, and stool consistency. Linaclotide was generally well-tolerated, and the safety profile is consistent with previously reported studies with linaclotide in FC and irritable bowel syndrome, or IBS, in pediatric patients. In this study, a total of 330 patients were randomized in a 1:1 ratio between linaclotide or placebo. Topline data indicate that linaclotide showed a statistically significant and clinically meaningful improvement compared to placebo in 12-week SBM frequency rate, the primary endpoint. Linaclotide-treated patients demonstrated a greater than two-fold least squares mean change from baseline in SBMs/week compared to placebo. Stool consistency, as assessed by Bristol Stool Form Scale, or BSFS, scores, which was the secondary endpoint, also showed an improvement at weeks 12 with linaclotide compared to placebo. The least squares mean change from baseline at week 12 was 1.108 and 0.685 points, respectively. The BSFS is a 7-point scale ranging from 1 to 7. Overall, linaclotide was well tolerated. The most frequently reported treatment-emergent adverse event was diarrhea, which occurred in 4.3% of linaclotide-treated participants versus 1.8% in the placebo group. These data are from the FC cohort of the Phase III, multicenter, randomized, double-blind, parallel-group, safety, and efficacy study of linaclotide vs. placebo in children ages 6-17 years with FC. Participants in the FC cohort must have fulfilled modified Rome III Criteria for child/adolescent FC. Ironwood expects to share these Phase III trial data at upcoming scientific meetings and via peer-reviewed publications. LINZESS is developed and marketed by Ironwood and AbbVie in the United States and is indicated for the treatment of adults with IBS-C or CIC. It is not approved for use in patients less than 18 years of age.
--Coca-Cola price target raised to $76 from $72 at HSBC » 06:22 KO HSBC analyst Carlos Laboy… BofA starts --Lumentum at Buy on attractive valuation, improving product mix 06:20 LITE BofA analyst Vivek Arya initiated coverage of Lumentum with a Buy rating and $105 price target. The analyst states that while the company faces near-term macro and cyclical risk around China lockdowns and in Europe, he likes Lumentum's improving product mix with more data center and telco customers longer term. Arya further cites the stock's "attractive valuation" at 11-times forward earnings. Lumentum should also benefit from ongoing optical component industry consolidation, Arya states.